Medicus Pharma (NASDAQ:MDCX) Releases Earnings Results, Misses Estimates By $0.50 EPS

Medicus Pharma (NASDAQ:MDCX) issued its quarterly earnings data on Wednesday. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.50), Zacks reports.

Medicus Pharma Stock Up 1.4%

Shares of NASDAQ:MDCX traded up $0.01 during midday trading on Thursday, reaching $0.50. The company’s stock had a trading volume of 974,574 shares, compared to its average volume of 3,971,335. The business has a 50 day moving average price of $1.01 and a 200 day moving average price of $1.74. Medicus Pharma has a 1 year low of $0.37 and a 1 year high of $8.94. The firm has a market cap of $12.80 million, a price-to-earnings ratio of -0.23 and a beta of -1.58.

Wall Street Analyst Weigh In

MDCX has been the subject of a number of analyst reports. D. Boral Capital reissued a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $23.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new stake in shares of Medicus Pharma in the fourth quarter worth approximately $2,771,000. Jane Street Group LLC acquired a new position in shares of Medicus Pharma in the 4th quarter valued at $92,000. HRT Financial LP purchased a new stake in shares of Medicus Pharma during the 4th quarter valued at $42,000. Wilmington Savings Fund Society FSB increased its holdings in shares of Medicus Pharma by 100.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after buying an additional 25,622 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its holdings in shares of Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after buying an additional 17,611 shares during the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.